President Trump announced Friday that all 50 states will join the Medicaid "GENEROUS" model, a program that applies "most favored nation" (MFN) pricing to select drugs — meaning the U.S. would pay no more than the lowest price charged to any other affluent nation. The announcement, made alongside Health Secretary RFK Jr. and CMS Administrator Mehmet Oz, comes just weeks ahead of November's midterm elections, with cost-of-living concerns dominating voter sentiment.

The White House projects the initiative could save $529 billion over the next decade, and Trump suggested states could redirect those savings toward other healthcare improvements. However, experts are urging caution — the actual terms of the deals struck with pharmaceutical companies remain confidential, making independent verification of the savings claims nearly impossible.

Key Takeaways:

• Medicaid patients already pay minimal co-pays, but lower drug prices could meaningfully ease state budget pressures
• Kathy Hempstead of the Robert Wood Johnson Foundation warns the lack of transparency is blocking meaningful legislative action
• Concerns linger about whether these price cuts will outlast the current administration

Why it matters: If the savings projections hold up, this could reshape how the U.S. negotiates drug prices at scale. But without public disclosure of deal terms, policymakers, lawmakers, and patients are left taking the administration's word for it.